Picture loading failed.

Anti-CD19 therapeutic antibody (Pre-made Loncastuximab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Loncastuximab tesirine is an antibody-drug conjugate designed to target human CD19. It is a humanized monoclonal antibody and conjugated to SG3199, a pyrrolobenzodiazepine (PBD) dimer cytotoxin by a protease enzyme cleavable valine-alanine linker.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-320-1mg 1mg 3090
GMP-Bios-ab-320-10mg 10mg 21890
GMP-Bios-ab-320-100mg 100mg 148000
GMP-Bios-ab-320-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD19 therapeutic antibody (Pre-made Loncastuximab biosimilar,Whole mAb ADC)
INN Name Loncastuximab
TargetCD19
FormatWhole mAb ADC
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI Structure6ani:HL:IM
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesADC Therapeutics
Conditions Approvedna
Conditions ActiveDiffuse large B cell lymphoma;Follicular lymphoma;Mantle-cell lymphoma;Non-Hodgkin's lymphoma
Conditions DiscontinuedPrecursor B-cell lymphoblastic leukaemia-lymphoma
Development Techna